1Maddrey WC. Hepatitis B: an important public heahh issue. J Med Virol,2000, 61 ( 3 ) : 362 - 366
2Mast EE, Alter M J, Margolis HS. Strategies to prevent and control hepatitis B and C virus infection: a global perspective. Vaccine, 1999, 17( 13 - 14) :1730 - 1733.
3Xu DZ, Yan YP, Choi BC, et al. Risk factors and mechanism of trasplacental transmission of hepatitis B virus: a case - control study. J Med VIROL, 2002,67( 1 ) :20 -26
4Chen WH, Yin CS, Chang YK, et al. Neonatal gastric aspirate as a predictor of perinatal hepatitis B virus infections. Int J Gynacol Obstet, 1998,60(1) :15 -21
5Van Nunen AB, De Man RA, Heijmk RA, et al. Lamivudine in the last 4 weeks of pregnany to prevent perinatal transmission in highly viremic chronic hepatitis B patients. J of Hepatology, 2000, 32 : 1040 - 1042
3Lai CL, Liaw YF, Leung NWY, et al. Genotypic resistance to lamivudine in a prospective, placebo-controlled multicentral study in Asia of lamivudine therapy for chronic hepatitis B infection. incidence, kinetics of emergency, and correlation with disease parameters. Hepatology,1997,26:259A.
4Lan DT, K hokhar MF, Dov E, et al. Long-time therapy of chronic hepatitis B with lamivudine. Hepatology,2000,32: 828-834.
5ai CL, Chien CK,Tung AKM, et al.Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo - controlled trial[J]. Hepatology, 1997,25 : 241 - 244.
